Healthy Volunteers Clinical Trial
Official title:
A Prospective Single-Site Non-Interventional Study to Evaluate the Diagnostic Accuracy and Repeatability of Pupil Measurements Using a Prototype Binocular Optical Coherence Tomography System.
Verified date | April 2018 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In current, clinical ophthalmology, a range of specialised testing allows comprehensive
evaluation of ocular health. These tests have typically evolved over many years to ensure
their clinical validity. For example, the assessment of visual acuity has traditionally been
measured with Snellen letter charts from a distance of six metres (20 feet), leading to the
phrase "20/20 vision". Despite this, the limitations of Snellen testing are well established
and more sophisticated testing is now available (e.g., logMAR testing using ETDRS (Early
Treatment Diabetic Retinopathy Study) charts). Many other diagnostic tests have undergone
similar cycles of refinement, often over extended time periods. Therefore, it should be
incumbent on any new device to undergo detailed evaluation of its validity (how its
measurements agree with other testing) and its repeatability (the variability when a further
measurement is obtained in short time period, by the same operator and under the same
conditions).
Binocular OCT extends the application of OCT devices beyond that of simple, cross- sectional
imaging to a diverse array of diagnostic tests. The binocular design also removes the need
for additional personnel to perform testing (i.e., the device can be self-operated in an
automated manner), and allows for novel testing to be performed that is not possible with
monocular imaging. In particular, binocular OCT devices have the potential to perform
automated, quantitative pupillary measurements - an entirely novel application for this
imaging modality.
This study will assess the validity and repeatability of pupil measurements using binocular
OCT.
Status | Completed |
Enrollment | 100 |
Est. completion date | November 30, 2017 |
Est. primary completion date | November 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria for participants with eye disease will include: - Presence of RAPD as measured with RAPDx - Presence of retinal disease, glaucoma or neuro-ophthalmic conditions that affect the optic nerve - Male or female, aged 18 years or older - Ability to understand nature/purpose of the study and to provide informed consent - Ability to undergo binocular OCT imaging - Ability to follow instructions and complete the study - Ability to speak English Exclusion criteria for participants with eye disease will include: - Optical media opacity sufficient to preclude adequate ocular imaging with OCT - Ptosis (drooping of the upper eyelid) sufficient to preclude visualization of the pupils using OCT - Significant pupil irregularity that precludes reliable measurement of RAPD - Any condition that is likely to interfere with pupillary constriction (e.g., iris pathology) - Hearing impairment sufficient to interfere with hearing instructions - Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct. Inclusion criteria for healthy subjects will include: - No self-reported ocular history (although wearing corrective prescription glasses is permitted) - Male or female, aged 18 years or older - Ability to understand nature/purpose of the study and to provide informed consent - Ability to undergo binocular OCT imaging - Ability to follow instructions and complete the study - Ability to speak English Exclusion criteria for healthy subjects will include: - Presence of ocular pathology, including ptosis or pupil irregularities - Hearing impairment sufficient to interfere with hearing instructions - Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Moorfields Eye Hospital NHS FT | London |
Lead Sponsor | Collaborator |
---|---|
University College, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy of the binocular OCT | The primary objective will be to determine the diagnostic accuracy of a prototype binocular OCT system for the detection of relative afferent pupillary defect (RAPD). | 6 months | |
Secondary | Test-retest variability of the binocular OCT pupillometry assessment | The secondary objective will be to assess the repeatability (test-retest variability) of pupillary assessment using this prototype binocular OCT system. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |